Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71:7–33.

Article  PubMed  Google Scholar 

Fahad Ullah M. Breast Cancer: Current Perspectives on the Disease Status. Adv Exp Med Biol. 2019;1152:51–64.

Article  CAS  PubMed  Google Scholar 

Scully OJ, Bay BH, Yip G, Yu Y. Breast cancer metastasis. Cancer Genomics Proteomics. 2012;9:311–20.

CAS  PubMed  Google Scholar 

Kozłowski J, Kozłowska A, Kocki J. Breast cancer metastasis - insight into selected molecular mechanisms of the phenomenon. Postepy Hig Med Dosw (Online). 2015;69:447–51.

Article  PubMed  Google Scholar 

Fares J, Fares MY, Khachfe HH, Salhab HA, Fares Y. Molecular principles of metastasis: a hallmark of cancer revisited. Signal Transduct Target Ther. 2020;5:28.

Article  PubMed  PubMed Central  Google Scholar 

Ganesh K, Massagué J. Targeting metastatic cancer. Nat Med. 2021;27:34–44.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–52.

Article  CAS  PubMed  Google Scholar 

Parker JS, Mullins M, Cheang MCU, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, et al. Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes. J Clin Oncol. 2009;27:1160–7.

Article  PubMed  PubMed Central  Google Scholar 

Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. Hum Pathol. 2008;39:167–74.

Article  CAS  PubMed  Google Scholar 

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F. Breast cancer Nat Rev Dis Primers. 2019;5:66.

Article  PubMed  Google Scholar 

Badve S, Dabbs DJ, Schnitt SJ, Baehner FL, Decker T, Eusebi V, Fox SB, Ichihara S, Jacquemier J, Lakhani SR, et al. Basal-like and triple-negative breast cancers: a critical review with an emphasis on the implications for pathologists and oncologists. Mod Pathol. 2011;24:157–67.

Article  PubMed  Google Scholar 

Foulkes William D, Smith Ian E, Reis-Filho Jorge S: Triple-negative breast Cancer. New Engl J Med. 2010;363:1938–48.

Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-Negative Breast Cancer: Clinical Features and Patterns of Recurrence. Clin Cancer Res. 2007;13:4429–34.

Article  PubMed  Google Scholar 

Carey L, Winer E, Viale G, Cameron D, Gianni L. Triple-negative breast cancer: disease entity or title of convenience? Nat Rev Clin Oncol. 2010;7:683–92.

Article  PubMed  Google Scholar 

Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40:537–47.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ye F, Dewanjee S, Li Y, Jha NK, Chen Z-S, Kumar A. Vishakha, Behl T, Jha SK, Tang H: Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bardia A, Hurvitz Sara A, Tolaney Sara M, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai Sagar D, Kalinsky K, Zelnak Amelia B, et al. Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. N Engl J Med. 2021;384:1529–41.

Article  CAS  PubMed  Google Scholar 

Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer — expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91–113.

Article  CAS  PubMed  Google Scholar 

Cortes J, Rugo Hope S, Cescon David W, Im S-A, Yusof Mastura M, Gallardo C, Lipatov O, Barrios Carlos H, Perez-Garcia J, Iwata H, et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2022;387:217–26.

Article  CAS  PubMed  Google Scholar 

Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im S-A, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. The Lancet. 2020;396:1817–28.

Article  Google Scholar 

Schmid P, Adams S, Rugo Hope S, Schneeweiss A, Barrios Carlos H, Iwata H, Diéras V, Hegg R, Im S-A, Shaw Wright G, et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379:2108–21.

Article  CAS  PubMed  Google Scholar 

da Cunha SG, Shepherd FA, Tsao MS. EGFR mutations and lung cancer. Annu Rev Pathol. 2011;6:49–69.

Article  Google Scholar 

Wang Z. ErbB Receptors and Cancer. Methods Mol Biol. 2017;1652:3–35.

Article  CAS  PubMed  Google Scholar 

Rajaram P, Chandra P, Ticku S, Pallavi BK, Rudresh KB, Mansabdar P. Epidermal growth factor receptor: Role in human cancer. Indian J Dent Res. 2017;28:687–94.

Article  PubMed  Google Scholar 

Levva S, Kotoula V, Kostopoulos I, Manousou K, Papadimitriou C, Papadopoulou K, Lakis S, Koukoulias K, Karavasilis V, Pentheroudakis G, et al. Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. Cancer Genomics Proteomics. 2017;14:181–95.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, Kim JH, Kang E, Kim SW, Kim IA, Park SY. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014;27:1212–22.

Article  CAS  PubMed  Google Scholar 

Nakajima H, Ishikawa Y, Furuya M, Sano T, Ohno Y, Horiguchi J, Oyama T. Protein expression, gene amplification, and mutational analysis of EGFR in triple-negative breast cancer. Breast Cancer. 2014;21:66–74.

Article  PubMed  Google Scholar 

Ueno NT, Zhang D. Targeting EGFR in Triple Negative Breast Cancer. J Cancer. 2011;2:324–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakai K, Hung MC, Yamaguchi H. A perspective on anti-EGFR therapies targeting triple-negative breast cancer. Am J Cancer Res. 2016;6:1609–23.

CAS  PubMed  PubMed Central  Google Scholar 

Carey LA, Rugo HS, Marcom PK, Mayer EL, Esteva FJ, Ma CX, Liu MC, Storniolo AM, Rimawi MF, Forero-Torres A, et al. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer. J Clin Oncol. 2012;30:2615–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rothlein R, Dustin ML, Marlin SD, Springer TA. A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol. 1986;137:1270–4.

Article  CAS  PubMed  Google Scholar 

Staunton DE, Marlin SD, Stratowa C, Dustin ML, Springer TA. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell. 1988;52:925–33.

Article  CAS  PubMed  Google Scholar 

Bella